Literature DB >> 17369067

A simple and inexpensive particle agglutination test to distinguish recent from established HIV-1 infection.

Hong Li1, Fassil Ketema, Anne M Sill, Kristen M Kreisel, Farley R Cleghorn, Niel T Constantine.   

Abstract

OBJECTIVES: We sought to modify the Serodia HIV-1/HIV-2 particle agglutination assay (PA), a simple and cost-effective HIV assay that is used globally for the detection of HIV antibodies, as a sensitive/less sensitive test (S/LS) to identify recently infected individuals and to estimate HIV incidence.
METHODS: The Serodia PA test was modified as an S/LS test (PA-LS) by using HIV antigen-coated gelatin particles at a dilution of 1:68 and a specific diluent, and calibrated using 37 HIV clade B seroconversion panels (309 samples) from Trinidad and from a commercial source that were tested at dilution intervals from 1:10 to 1:80,000. The greatest sensitivity for correctly classifying samples from recent and established infections was determined by receiver operator curve (ROC) analysis.
RESULTS: At a 1:40,000 sample dilution and a days post-seroconversion cutoff of 190 days, the PA-LS test yielded a 97% sensitivity for classifying recent and established infection samples. Furthermore, at a 1:20,000 dilution, the positive predictive value for correctly identifying recently infected individuals was 99%. The PA-LS test offers a 30-44-fold cost saving over currently available S/LS tests.
CONCLUSION: A modified, low cost and simple-to-perform PA test is appropriate for use in resource-limited countries, and has exhibited excellence in distinguishing recent from established HIV infection.

Entities:  

Mesh:

Year:  2007        PMID: 17369067     DOI: 10.1016/j.ijid.2006.12.010

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  8 in total

1.  Estimating HIV Incidence in Populations Using Tests for Recent Infection: Issues, Challenges and the Way Forward.

Authors:  Timothy D Mastro; Andrea A Kim; Timothy Hallett; Thomas Rehle; Alex Welte; Oliver Laeyendecker; Tom Oluoch; Jesus M Garcia-Calleja
Journal:  J HIV AIDS Surveill Epidemiol       Date:  2010-01-01

Review 2.  Diagnosis of Human Immunodeficiency Virus Infection.

Authors:  Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

3.  The effect of viral suppression on cross-sectional incidence testing in the johns hopkins hospital emergency department.

Authors:  Oliver Laeyendecker; Richard E Rothman; Charlamaine Henson; Bobbi Jo Horne; Kerunne S Ketlogetswe; Chadd K Kraus; Judy Shahan; Gabor D Kelen; Thomas C Quinn
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

4.  HIV incidence determination in the United States: a multiassay approach.

Authors:  Oliver Laeyendecker; Ron Brookmeyer; Matthew M Cousins; Caroline E Mullis; Jacob Konikoff; Deborah Donnell; Connie Celum; Susan P Buchbinder; George R Seage; Gregory D Kirk; Shruti H Mehta; Jacquie Astemborski; Lisa P Jacobson; Joseph B Margolick; Joelle Brown; Thomas C Quinn; Susan H Eshleman
Journal:  J Infect Dis       Date:  2012-11-05       Impact factor: 5.226

5.  Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection.

Authors:  Vladimir Novitsky; Rui Wang; Lemme Kebaabetswe; Jamieson Greenwald; Raabya Rossenkhan; Sikhulile Moyo; Rosemary Musonda; Elias Woldegabriel; Stephen Lagakos; M Essex
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731

Review 6.  Current and future assays for identifying recent HIV infections at the population level.

Authors:  Joanna Smoleń-Dzirba; Tomasz J Wąsik
Journal:  Med Sci Monit       Date:  2011-05

Review 7.  Moving towards a reliable HIV incidence test - current status, resources available, future directions and challenges ahead.

Authors:  G Murphy; C D Pilcher; S M Keating; R Kassanjee; S N Facente; A Welte; E Grebe; K Marson; M P Busch; P Dailey; N Parkin; J Osborn; S Ongarello; K Marsh; J M Garcia-Calleja
Journal:  Epidemiol Infect       Date:  2016-12-22       Impact factor: 4.434

8.  Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes.

Authors:  Yen T Duong; Reshma Kassanjee; Alex Welte; Meade Morgan; Anindya De; Trudy Dobbs; Erin Rottinghaus; John Nkengasong; Marcel E Curlin; Chonticha Kittinunvorakoon; Boonyos Raengsakulrach; Michael Martin; Kachit Choopanya; Suphak Vanichseni; Yan Jiang; Maofeng Qiu; Haiying Yu; Yan Hao; Neha Shah; Linh-Vi Le; Andrea A Kim; Tuan Anh Nguyen; William Ampofo; Bharat S Parekh
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.